Literature DB >> 21567425

Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy.

Cheng-Chao Liang1, Chen-Hua Liu, Yu-Li Lin, Chun-Jen Liu, Bor-Luen Chiang, Jia-Horng Kao.   

Abstract

Although chronic hepatitis C patients have a lower frequency and functions of dendritic cells (DCs) than healthy subjects, little is known about the serial changes in frequency and functions of DCs following anti-viral treatment and the relationship with treatment outcomes. Twenty patients with hepatitis C virus genotype 1 receiving peginterferon (PEG-IFN) and ribavirin for 24 weeks were enrolled. The frequency and functions of DCs were assayed at baseline and 24 weeks post-treatment. Ten sex and age-matched healthy adults served as controls. Nineteen of the 20 chronic hepatitis C patients completed 24 weeks of combination therapy. Fifteen patients achieved rapid virologic response and 12 achieved sustained virologic response (SVR). The baseline frequency of peripheral blood myeloid DCs and plasmacytoid DCs was significantly lower in chronic hepatitis C patients than in healthy controls. In patients who achieved SVR, the frequency of DCs subsets at the end of follow-up increased to a level comparable to healthy controls. Although no functional defects of DCs was found in chronic hepatitis C patients in comparison with healthy controls, in patients without SVR had a lower CD83 expression and higher interleukin-10 production of DCs than SVR patients. The results suggest that low CD83 expression and high IL-10 production of DCs at the baseline may predict a poor virologic response to 24-week PEG-IFN plus ribavirin therapy in HCV genotype 1 patients.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567425     DOI: 10.1002/jmv.22096

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

Review 1.  Current progress in host innate and adaptive immunity against hepatitis C virus infection.

Authors:  Jijing Shi; Yuanyuan Li; Wenxian Chang; Xuexiu Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2017-06-22       Impact factor: 6.047

Review 2.  Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C.

Authors:  Andrea Crosignani; Antonio Riva; Silvia Della Bella
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

3.  Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.

Authors:  Mohit Sehgal; Marija Zeremski; Andrew H Talal; Zafar K Khan; Renold Capocasale; Ramila Philip; Pooja Jain
Journal:  J Clin Cell Immunol       Date:  2014-10-31

Review 4.  Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?

Authors:  Mohit Sehgal; Zafar K Khan; Andrew H Talal; Pooja Jain
Journal:  Virology (Auckl)       Date:  2013-02-11

Review 5.  IL-10: A Multifunctional Cytokine in Viral Infections.

Authors:  José M Rojas; Miguel Avia; Verónica Martín; Noemí Sevilla
Journal:  J Immunol Res       Date:  2017-02-20       Impact factor: 4.818

6.  Valine, a branched-chain amino Acid, reduced HCV viral load and led to eradication of HCV by interferon therapy in a decompensated cirrhotic patient.

Authors:  Takumi Kawaguchi; Takuji Torimura; Akio Takata; Susumu Satomi; Michio Sata
Journal:  Case Rep Gastroenterol       Date:  2012-10-24

Review 7.  Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C.

Authors:  Phyllis T Losikoff; Alyssa A Self; Stephen H Gregory
Journal:  Virulence       Date:  2012-10-17       Impact factor: 5.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.